U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07225374) titled 'Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC' on Sept. 16.
Brief Summary: A Prospective Phase II Study of Adjuvant Cisplatin-Based Chemotherapy followed by Maintenance Avelumab in Upper Tract Urothelial Carcinoma
Study Start Date: Sept. 16
Study Type: INTERVENTIONAL
Condition:
Upper Tract Urothelial Carcinoma
Intervention:
DRUG: Avelumab 10 mg/kg
Patients who meet all of the inclusion criteria and none of the exclusion criteria will receive avelumab 10 mg/kg as a
1-h infusion every 2 weeks. Avelumab will repeat every 2 weeks on an outpatient basis and continued until disease recurrence, unacceptable t...